In Brief: Affymetrix
Executive Summary
Affymetrix: Firm is negotiating with Glaxo to become an independent entity, Affymetrix President and CEO David Singer tells Alex. Brown Health Care Seminar May 16 in Baltimore. Glaxo assumed Affymax' 65% interest in Affymetrix when it acquired Affymax in January ("The Pink Sheet" Jan. 30, p. 12). Affymetrix has retained independent operations since the Glaxo acquisition. Glaxo and Affymetrix are currently exploring the possibility of a genomics collaboration, Singer indicated...